Special Issue

Advanced Research in Heme Oxygenase

Message from the Guest Editors

Heme oxygenase (Hmox) has been studied for many decades and is known to be the enzyme responsible for the breakdown of heme, which occurs in all cells in the body. It generates carbon monoxide (CO), biliverdin, which is reduced by biliverdin reductase to bilirubin, and free iron. Heme oxygenase and its related enzymes and metabolites play an important role in several physiological and pathological processes, including cancer, diabetes, heart and kidney disease, hypertension, inflammation, obesity, and neurological diseases. This Special Issue solicits exciting new advances in heme oxygenase biology, its related enzymes for synthesis or catabolism, and its metabolites. The latest in preclinical and clinical trials and timely reviews highlighting the importance of heme oxygenase and its related metabolites will be incorporated into the Special Issue. The goal is to expand upon what has been known about Hmox and extend this into new advancements, whether that might be detection instruments, new ligand agonists or antagonists, and possible new discoveries not yet known.

Guest Editors

Dr. Terry D Hinds, Jr.

Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40508, USA

Dr. David E. Stec

Center for Excellence in Cardiovascular-Renal Research, Department of Physiology & Biophysics, University of Mississippi Medical Center, 2500 North State St., Jackson, MS 392161, USA

Deadline for manuscript submissions

closed (31 July 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/158684

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).